Defence Therapeutics Inc. (DTCFF)
- Previous Close
0.8300 - Open
0.8300 - Bid 0.6707 x --
- Ask 0.7615 x --
- Day's Range
0.8300 - 0.8300 - 52 Week Range
0.8118 - 3.1900 - Volume
1,230 - Avg. Volume
399 - Market Cap (intraday)
37.795M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
defencetherapeutics.comRecent News: DTCFF
Performance Overview: DTCFF
Trailing total returns as of 6/11/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DTCFF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DTCFF
Valuation Measures
Market Cap
35.08M
Enterprise Value
35.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-403.56%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.57M
Diluted EPS (ttm)
-0.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
514.53k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.33M